ID
37674
Beschreibung
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form is to be filled with data regarding pharmacodynamic results relating to the coagulation system and lung epithelial cell injury, taken repeatedly on Day 1 and 3, and can also be used for repeat analyses.
Link
https://clinicaltrials.gov/ct2/show/NCT00996840
Stichworte
Versionen (2)
- 13.08.19 13.08.19 -
- 15.08.19 15.08.19 - Sarah Riepenhausen
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
15. August 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Pharmacodynamics Results
- StudyEvent: ODM
Ähnliche Modelle
Pharmacodynamics Results
- StudyEvent: ODM
C1254595 (UMLS CUI-2)
C0304229 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C1264639 (UMLS CUI [1,2])
C0031328 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0525032 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0525032 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,2])
C0491338 (UMLS CUI [1,3])
C0491338 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0491338 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0030605 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0030605 (UMLS CUI [1,3])